Navigation Links
Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
Date:11/4/2013

JERUSALEM, Nov. 4, 2013 /PRNewswire/ -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that its portfolio company Enlivex has published a scientific paper in the official publication of the American Society for Blood and Marrow Transplantation - 'Biology of Blood and Marrow Transplantation'. Hadasit Bio-Holdings holds a 92% stake in Enlivex.

The peer-reviewed paper provides additional validation to the Phase I/II results and emphasizes the significance of its findings.  The findings were based on a 13 patient trial conducted in three clinical centers in Israel.  The patients were given four escalating doses of ApoCell, Enlivex's lead product, shortly before a bone marrow transplant from a foreign donor. No safety concerns were observed in any of the doses and GvHD morbidity levels were significantly reduced. 

One of the main concerns in receiving bone marrow transplants from a donor is Graft-versus-Host Disease (GvHD). GvHD is an auto-immune type disease in which the immune system, including the new transplant, attacks organs of the patient, primarily the liver, intestines and skin. The disease can cause significant morbidity and is usually fatal if a patient reaches high grades. To date, no effective treatment has been found for this disease and up to 70% of transplant recipients suffer from this illness.

ApoCell is based on a cellular treatment developed in Hadassah Ein Kerem by Prof. Dror Mevorach, an expert in diseases of the immune system. The treatment is based on normal biological activity and initiates a state of 'immune tolerance' allowing the implant to fight the patients' cancer while significantly reducing the GvHD severity.

Alon Moran, CEO of Enlivex, stated, "We are very proud of this recognition by a leading journal in the field of bone marrow transplantation and believe this direct exposure to the scientific and medical community will increase awareness of our novel and effective treatment for GvHD."

As previously reported, Enlivex Therapeutics was recently awarded orphan drug status by the FDA for its ApoCell treatment.  The orphan drug designation provides for seven years of exclusivity, guaranteeing no competition irrespective of patents and significant regulatory relief, which will likely shorten the marketing approval of the drug in the U.S. and reduce costs.

Ophir Shahaf, CEO of Hadasit Bio-Holdings, commented, "This is an outstanding scientific achievement in showing Enlivex's potential but more importantly, validating ApoCell's safety and efficacy in preventing a disease that has no cure. The next step in drug development will be a Phase II/b under an IND from the FDA. We continue to garner interest from a number of parties as we develop this treatment for a market estimated at hundreds of millions of dollars a year."

For more information about Enlivex and ApoCell please visit: www.enlivexpharm.com

For more information about Hadasit Bio-Holdings please visit: www.hbl.co.il

Contact: 
KCSA Strategic Communications 
Phil Carlson / Josh Dver 
212-896-1233 / 1239 
pcarlson@kcsa.com / jdver@kcsa.com


'/>"/>
SOURCE Hadasit Bio-Holdings Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hadasit Bio-Holdings Flagship Portfolio Company Enlivex Awarded Orphan Drug Status for ApoCell Treatment by the FDA
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
Breaking Medicine News(10 mins):